成全在线观看免费完整的,成全影视大全免费追剧大全,成全视频高清免费播放电视剧好剧,成全在线观看免费完整,成全在线观看高清全集,成全动漫视频在线观看完整版动画

×

Open WeChat and scan the QR code
Subscribe to our WeChat public account

HOME Overview Professional Fields Industry Fields Professionals Global Network News Publications Join Us Contact Us Subscribe CN EN JP
HOME > Publications > Newsletter > Implementing Rules for Human Genetic Resources Released by Ministry of Science and Technology

Implementing Rules for Human Genetic Resources Released by Ministry of Science and Technology

 2023-08-312689

ISSUING AUTHORITY:

The Ministry of Science and Technology

DATE OF ISSUANCE:

June 1, 2023

EFFECTIVE DATE:

July 1, 2023

 

On June 1, 2023, China’s Ministry of Science and Technology (MOST) officially released the Implementation Rules for the Regulation on Human Genetic Resources Administration (the “Implementation Rules”), which came into effect on July 1, 2023.

 

The Implementation Rules, which were built upon the earlier draft version issued by MOST on March 21, 2022, address various concerns and issues that have emerged since the implementation of the Administrative Regulations on Human Genetic Resources in 2019.

 

Firstly, the Implementation Rules specify the scope of human genetic resources (“HGR”) information. In Article 2 of the Implementation Rules, HGR information refers to “human genes, genome data and other information generated by using HGR materials,” and specifically excludes clinical data, imaging data, protein data, and metabolic data.

 

Secondly, the Implementation Rules have narrowed the scope of collection approval by excluding common diseases such as hypertension, diabetes, color blindness, and hemophilia from the regulation of important genetic lineages. The Implementation Rules also eliminate the collection approval requirements for specific categories of HGR, such as rare diseases, and increase the minimum collection threshold that necessitates approval. Furthermore, the rules provide exemptions for international collaborative clinical trials conducted for obtaining drug or medical device marketing approval.

 

In addition, the Implementation Rules have introduced streamlined approval procedures for international scientific research collaborations to facilitate smoother cooperation. The newly introduced Article 53 of the Implementation Rules supplements the provisions for non-significant changes. The parties involved in non-significant changes are required to submit relevant materials to MOST for explanation and filing, without the need for approval for the changes.

 

In general, the Implementation Rules have streamlined the application process for HGR-related activities, taking into account the industry’s concerns and practical needs. However, the Implementation Rules also reflect MOST’s increased focus on strengthening the regulation of HGR.

 


Reference:

科學(xué)技術(shù)部令第21號(hào)《人類(lèi)遺傳資源管理?xiàng)l例實(shí)施細(xì)則》


欢迎光临: 沁水县| 磐石市| 齐齐哈尔市| 新乡县| 宁德市| 南乐县| 长治市| 海南省| 平罗县| 北海市| 香河县| 泰和县| 河西区| 修武县| 怀集县| 怀柔区| 黑河市| 大埔县| 边坝县| 香河县| 太仓市| 虞城县| 思茅市| 高雄县| 长治市| 乌拉特中旗| 皋兰县| 罗甸县| 刚察县| 容城县| 阿拉善右旗| 柘荣县| 蒙山县| 海口市| 普兰县| 凉山| 乡宁县| 安义县| 浦城县| 襄樊市| 宣恩县|